

Sylvie D Freeman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8076129/publications.pdf>

Version: 2024-02-01

39
papers

3,455
citations

430754

18
h-index

414303

32
g-index

39
all docs

39
docs citations

39
times ranked

3038
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. <i>Haematologica</i> , 2022, 107, 1518-1527.	1.7	18
2	Delving the depths of measurable residual disease negativity in acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 2776-2778.	1.7	1
3	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. <i>HemaSphere</i> , 2022, 6, e676.	1.2	35
4	Transplant in older adults with AML: genomic wheat and chaff. <i>Blood</i> , 2022, 139, 3459-3461.	0.6	1
5	Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 2208-2217.	3.3	8
6	How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). <i>British Journal of Haematology</i> , 2021, 193, 231-244.	1.2	31
7	Future Developments: Measurable Residual Disease. <i>Hematologic Malignancies</i> , 2021, , 317-337.	0.2	0
8	Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 768-778.	0.8	95
9	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. <i>Journal of Clinical Oncology</i> , 2021, 39, 890-901.	0.8	20
10	Selection of Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplasia - New Evidence Emerges. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 443-445.	0.6	5
11	Reply to G. Gui et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 2416-2417.	0.8	1
12	How Can We Improve on MRD Assessment by Flow Cytometry?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S49-S50.	0.2	0
13	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2021, 138, 2753-2767.	0.6	305
14	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2020, 6, 1890.	3.4	207
15	Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. <i>British Journal of Haematology</i> , 2020, 190, 891-900.	1.2	11
16	Molecular MRD status and outcome after transplantation in NPM1-mutated AML. <i>Blood</i> , 2020, 135, 680-688.	0.6	109
17	Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up. <i>Blood</i> , 2020, 136, 35-35.	0.6	1
18	Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies. <i>Blood</i> , 2020, 136, 16-17.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
20	Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. <i>Journal of Experimental Medicine</i> , 2019, 216, 966-981.	4.2	91
21	MRD evaluation of AML in clinical practice: are we there yet?. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 557-569.	0.9	27
22	Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 3052-3061.	2.5	15
23	Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults. <i>British Journal of Haematology</i> , 2019, 186, 130-133.	1.2	7
24	The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial. <i>Blood</i> , 2019, 134, 2031-2031.	0.6	4
25	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018, 131, 1275-1291.	0.6	796
26	No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials. <i>Blood</i> , 2018, 131, 468-471.	0.6	36
27	Evaluating measurable residual disease in acute myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 1356-1366.	2.5	132
28	Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 215.	1.7	22
29	Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without <i>NPM1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 1486-1497.	0.8	151
30	Pre-Transplant <i>NPM1</i> Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on <i>FLT3</i> ITD Status. <i>Blood</i> , 2018, 132, 2739-2739.	0.6	2
31	Assessment of Minimal Residual Disease in Standard-Risk AML. <i>New England Journal of Medicine</i> , 2016, 374, 422-433.	13.9	662
32	Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, <i>BCL2</i> and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016, 11, e0163291.	1.1	11
33	An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34 ⁺ CD38 ^{low} blasts. <i>British Journal of Haematology</i> , 2015, 170, 80-84.	1.2	12
34	Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for 'prime time'. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 222-233.	0.9	48
35	Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for 'prime time'. <i>Blood</i> , 2014, 124, 3345-3355.	0.6	220
36	Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 4123-4131.	0.8	280

#	ARTICLE	IF	CITATIONS
37	Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia. Blood, 2011, 118, 638-638.	0.6	5
38	Detection of Immunophenotypic Residual Disease After Induction Therapy Is An Independent Prognostic Factor for Duration of Remission In Older AML Patients Treated Intensively. Blood, 2010, 116, 2714-2714.	0.6	0
39	Development of Minimal Residual Diseaseâ€Directed Therapy in Acute Myeloid Leukemia. Seminars in Oncology, 2008, 35, 388-400.	0.8	86